The physiological membrane potential as work energy von Kerstein, F.W.

Volltext

Morphometric analysis on myocardial injury related to the use of high volume potassium cardioplegic solution during ischemic arrest von Li, Qui-yan, MacAulay, M.A., Landymore, R.W., Marble, A., Dean, S., Fris, J., Kerstein, F.

Volltext

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer von Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James Chih-Hsin, Han, Ji-Youn, Lee, Jong-Seok, Hochmair, Maximilian J, Li, Jacky Yu-Chung, Chang, Gee-Chen, Lee, Ki Hyeong, Gridelli, Cesare, Delmonte, Angelo, Garcia Campelo, Rosario, Kim, Dong-Wan, Bearz, Alessandra, Griesinger, Frank, Morabito, Alessandro, Felip, Enriqueta, Califano, Raffaele, Ghosh, Sharmistha, Spira, Alexander, Gettinger, Scott N, Tiseo, Marcello, Gupta, Neeraj, Haney, Jeff, Kerstein, David, Popat, Sanjay

Volltext

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial von Huber, Rudolf M., Hansen, Karin H., Paz-Ares Rodríguez, Luis, West, Howard L., Reckamp, Karen L., Leighl, Natasha B., Tiseo, Marcello, Smit, Egbert F., Kim, Dong-Wan, Gettinger, Scott N., Hochmair, Maximilian J., Kim, Sang-We, Langer, Corey J., Ahn, Myung-Ju, Kim, Edward S., Kerstein, David, Groen, Harry J.M., Camidge, D. Ross

Volltext

Type Ia Supernovae: Calculations of Turbulent Flames Using the Linear Eddy Model von Woosley, S. E, Kerstein, A. R, Sankaran, V, Aspden, A. J, Röpke, F. K

Volltext

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial von Kim, Dong-Wan, Tiseo, Marcello, Ahn, Myung-Ju, Reckamp, Karen L, Hansen, Karin Holmskov, Kim, Sang-We, Huber, Rudolf M, West, Howard L, Groen, Harry J M, Hochmair, Maximilian J, Leighl, Natasha B, Gettinger, Scott N, Langer, Corey J, Paz-Ares Rodríguez, Luis G, Smit, Egbert F, Kim, Edward S, Reichmann, William, Haluska, Frank G, Kerstein, David, Camidge, D Ross

Volltext

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease von Yale, J.-F., Bakris, G., Cariou, B., Nieto, J., David-Neto, E., Yue, D., Wajs, E., Figueroa, K., Jiang, J., Law, G., Usiskin, K., Meininger, G.

Volltext

Single-Column Model Intercomparison for a Stably Stratified Atmospheric Boundary Layer von Cuxart, J., Holtslag, A. A. M., Beare, R. J., Bazile, E., Beljaars, A., Cheng, A., Conangla, L., Ek, M., Freedman, F., Hamdi, R., Kerstein, A., Kitagawa, H., Lenderink, G., Lewellen, D., Mailhot, J., Mauritsen, T., Perov, V., Schayes, G., Steeneveld, G-J., Svensson, G., Taylor, P., Weng, W., Wunsch, S., Xu, K-M.

Volltext

Toward modeling of CO₂ multi-phase flow patterns using a stochastic multi-scale approach von Schulz, F. T, Glawe, C, Schmidt, H, Kerstein, A. R

Volltext

Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial von Califano, R., Hochmair, M.J., Gridelli, C., Delmonte, A., Garcia Campelo, M.R., Bearz, A., Griesinger, F., Morabito, A., Felip, E., Ghosh, S., Tiseo, M., Haney, J., Kerstein, D., Popat, S., Camidge, D.R.

Volltext

Numerical investigation of turbulent-jet primary breakup using one-dimensional turbulence von Movaghar, A., Linne, M., Oevermann, M., Meiselbach, F., Schmidt, H., Kerstein, Alan R.

Volltext

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial von Popat, S., Kim, H.R., Ahn, M.-J., Yang, J.C.-H., Han, J.-Y., Hochmair, M.J., Lee, K.H., Delmonte, A., Garcia Campelo, M.R., Kim, D.-W., Griesinger, F., Felip, E., Califano, R., Spira, A.I., Gettinger, S., Tiseo, M., Haney, J., Kerstein, D., Camidge, D.R.

Volltext

Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis von Kappes, Lucy, Amer, Ruba L., Sommerlatte, Sabine, Bashir, Ghada, Plattfaut, Corinna, Gieseler, Frank, Gemoll, Timo, Busch, Hauke, Altahrawi, Abeer, Al-Sbiei, Ashraf, Haneefa, Shoja M., Arafat, Kholoud, Schimke, Lena F., Khawanky, Nadia El, Schulze-Forster, Kai, Heidecke, Harald, Kerstein-Staehle, Anja, Marschner, Gabriele, Pitann, Silke, Ochs, Hans D., Mueller, Antje, Attoub, Samir, Fernandez-Cabezudo, Maria J., Riemekasten, Gabriela, al-Ramadi, Basel K., Cabral-Marques, Otavio

Volltext

A phase I open label study evaluating VT1021 in patients with advanced solid tumors von Cieslewicz, Michael, Mahalingam, Devalingam, Harb, Wael A., Patnaik, Amita, Liu, Joyce F., Juric, Dejan, Bullock, Andrea J., Zheng, Lei, Moore, Kathleen N., Patel, Manish R., Guttendorf, Robert, Wang, Suming, Kerstein, Kathy, Berk, Gregory Ivan, Watnick, Jing

Volltext

The Equal Employment Opportunity Commission proposal and the Genetic Information Nondiscrimination Act von Kerstein, Brett, Lambertson, Katherine

Volltext

106OBrigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial von Califano, R, Hochmair, M J, Gridelli, C, Delmonte, A, Garcia Campelo, M R, Bearz, A, Griesinger, F, Morabito, A, Felip, E, Ghosh, S, Tiseo, M, Haney, J, Kerstein, D, Popat, S, Camidge, D R

Volltext

Overview of wound healing in a moist environment von Field, Charles K., Kerstein, Morris D.

Volltext

LBA58Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial von Popat, S, Kim, H R, Ahn, M-J, Yang, J C-H, Han, J-Y, Hochmair, M J, Lee, K H, Delmonte, A, Garcia Campelo, M R, Kim, D-W, Griesinger, F, Felip, E, Califano, R, Spira, A I, Gettinger, S, Tiseo, M, Haney, J, Kerstein, D, Camidge, D R

Volltext

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain... von Huber, Rudolf M., Kim, Dong-Wan, Ahn, Myung-Ju, Langer, Corey J., Tiseo, Marcello, West, Howard, Groen, Harry J.M., Reckamp, Karen L., Hochmair, Maximilian J., Leighl, Natasha B., Holmskov Hansen, Karin, Gettinger, Scott N., Paz-Ares, Luis G., Kim, Edward S., Smit, Egbert F., Kim, Sang-We, Reichmann, William, Kerstein, David, Camidge, D. Ross

Volltext

Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial von Bazhenova, L., Gettinger, S., Langer, C., Salgia, R., Gold, K., Rosell, R., Shaw, A., Weiss, G., Haney, J., Rivera, V., Haluska, F., Kerstein, D., Camidge, D.R.

Volltext